News
13h
Zacks Investment Research on MSNGSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook RaiseGSK plc GSK reported second-quarter 2025 core earnings of $1.23 per American depositary share (ADS), which beat the Zacks ...
17h
Legit.ng on MSNGSK reports improved outlook despite US drug tariffsBritish pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, ...
BAE Systems also came under pressure, falling 24p to 1797p despite its upgrade to 2025 guidance. GSK also surrendered initial ...
GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage ...
GSK (LSE: GSK) posted a 6% rise in second-quarter sales to £8 billion ($10.7 billion), ahead of analyst forecasts. Pre-tax ...
GSK PLC GSK shares rose 4.69% to £14.63 Wednesday, on what proved to be an all-around favorable trading session for the stock ...
GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...
Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...
GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 ...
GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, regulatory and pipeline successes and an optimistic outlook for the long ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results